clinical trial · NCT05507515
A Phase 1 Study of ONO-2020 in Healthy Participants
Ono Pharmaceutical Co., Ltd.·phase1·completed·n = 132
Healthy VolunteersONO-2020Placebo
brief summary
The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.
started
Jul 29, 2022
primary completion
Dec 24, 2023
completion
Dec 24, 2023
last updated
Apr 9, 2024
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Five-part Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2020 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol